Risk of second primary cutaneous malignant melanoma in females with known breast cancer hormone receptor status: A nationwide U.S. patient population study

Introduction: Patients diagnosed with breast cancer may be at an increased risk for second primary malignant melanoma (SPCMM). The study aim was to determine the risk for SPCMM in those with known breast cancer receptor status: estrogen, ER(+) or ER(-), progesterone, PR(+) or PR(-), using the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) database.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research